Loading company…
Watertown-based developer of small-molecule drugs that target RNA and DNA processes in cancer and autoimmune disease.
Founded in 2016 and headquartered in Watertown, US, Twentyeight-Seven, Inc. develops small-molecule therapeutics for serious diseases, including cancer and autoimmune disorders. In May 2019 it raised USD 15.00 mn in Series A funding led by Sofinnova Partners, with participation from OUP (Osage University Partners). Its therapeutics are aimed at healthcare providers, pharmaceutical partners and patients, particularly in the United States and Europe.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in